DeepMed Research

Heidelberg Pharma AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1999-01-01

Employees: 105

Market Cap: -

Website: http://heidelberg-pharma.com

Clinical Trials

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Plasma Cell Disorder
Multiple Myeloma

Interventions: Drug: HDP-101

First Posted Date: 2021-05-10

Last Posted Date: 2024-07-24

Lead Sponsor: Heidelberg Pharma AG

Target Recruit Count: 78

Registration Number: NCT04879043

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Mount Sinai, The Tisch Cancer Instutute, New York, New York, United States
🇩🇪
Asklepios Klinik Altona, Haematologie und internistische Onkologie, Hamburg, Germany

and more 13 locations

Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

Phase 1

Terminated

Conditions: Advanced Solid Tumours

Interventions: Drug: WX-037
Drug: WX-554

First Posted Date: 2013-05-21

Last Posted Date: 2014-05-16

Lead Sponsor: Heidelberg Pharma AG

Target Recruit Count: 13

Registration Number: NCT01859351

Locations: 🇬🇧
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧
Guy's and St Thomas' Foundation Trust, Guy's Hospital, London, United Kingdom

REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

Phase 3

Withdrawn

Conditions: Kidney Cancer
Renal Cell Carcinoma

Interventions: Drug: Iodine (124I) Girentuximab

First Posted Date: 2013-01-07

Last Posted Date: 2017-12-22

Lead Sponsor: Heidelberg Pharma AG

Registration Number: NCT01762592

Locations: 🇺🇸
David Geffen School of Medicine, UCLA, Los Angeles, California, United States
🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 5 locations

Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours

Phase 1

Terminated

Conditions: Advanced Solid Tumours

Interventions: Drug: WX-554

First Posted Date: 2012-04-19

Last Posted Date: 2014-05-16

Lead Sponsor: Heidelberg Pharma AG

Target Recruit Count: 41

Registration Number: NCT01581060

Locations: 🇬🇧
St James' Institute of Oncology, Leeds, United Kingdom
🇬🇧
Sir Bobby Robson Cancer Trials Research Centre, Newcastle Upon Tyne, United Kingdom
🇬🇧
Queen's University Belfast Cancer Centre, Belfast, United Kingdom

and more 2 locations

Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: WX-671
Drug: placebo

First Posted Date: 2008-02-14

Last Posted Date: 2014-02-28

Lead Sponsor: Heidelberg Pharma AG

Target Recruit Count: 132

Registration Number: NCT00615940

Locations: 🇧🇪
AZ Klina, Oncology Department, Brasschaat, Belgium
🇧🇪
Institut Jules Bordet Oncologie Médicale, Bruxelles, Belgium
🇧🇪
CHU de Liège, Domaine Universitaire de Sart-Tilman, Oncology Department, Liège, Belgium

and more 17 locations

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

Phase 3

Completed

Conditions: Renal Cell Carcinoma
Kidney Cancer

Interventions: Drug: 124-Iodine-cG250 (124I-cG250)
Procedure: CT

First Posted Date: 2008-02-04

Last Posted Date: 2018-10-02

Lead Sponsor: Heidelberg Pharma AG

Target Recruit Count: 226

Registration Number: NCT00606632

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
David Geffen School of Medicine, UCLA, Los Angeles, California, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 11 locations

Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: Serine Proteinase Inhibitor WX-671

First Posted Date: 2007-07-11

Last Posted Date: 2012-03-29

Lead Sponsor: Heidelberg Pharma AG

Target Recruit Count: 95

Registration Number: NCT00499265

Locations: 🇭🇺
University of Pecs Faculty of Medicine, Pecs, Hungary
🇭🇺
Debreceni Egyetem Onkologiai Tanzek, Debrecen, Hungary
🇭🇺
Petz Aladar County Hospital, Gydr, Hungary

and more 36 locations

Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer

Phase 3

Completed

Conditions: Kidney Cancer

Interventions: Biological: girentuximab
Other: placebo

First Posted Date: 2004-07-12

Last Posted Date: 2018-11-27

Lead Sponsor: Heidelberg Pharma AG

Target Recruit Count: 864

Registration Number: NCT00087022

Locations: 🇺🇸
Southeastern Research Group, Tallahassee, Florida, United States
🇺🇸
Northeast Indiana Urology, PC, Fort Wayne, Indiana, United States
🇺🇸
Vermont Cancer Center at University of Vermont, Burlington, Vermont, United States

and more 52 locations

Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Malignancies

First Posted Date: 2004-05-26

Last Posted Date: 2008-01-24

Lead Sponsor: Heidelberg Pharma AG

Target Recruit Count: 33

Registration Number: NCT00083525

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy